COMMUNIQUÉS West-GlobeNewswire

Thinking About a Facelift? Announcing a Skincare Range Specifically Created for Mature Women: The Azul SkinHealth Anti-Aging System
06/02/2018
NAPLES, Fla., Feb. 06, 2018 (GLOBE NEWSWIRE) -- As any one of the thousands of “snow birds” who flock to Florida for the winter will tell you, the Sunshine State, with its enviable climate, does have a downside – skin [...]
Xbrane Biopharma signs license agreement with CR Pharma for Spherotide in China
06/02/2018
Press release 2018-02-06 Xbrane Biopharma (publ.) ("Xbrane") and China Resource Pharmaceutical Group Limited ("CR Pharma") have entered into a license agreement which gives CR Pharma exclusive rights to market and sell [...]
ALK releases its annual report 2017
06/02/2018
Copenhagen, 2018-02-06 07:30 CET (GLOBE NEWSWIRE) -- The Board of Directors of ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) today considered and approved the 2017 annual report with the following highlights [1] : Q4 [...]
Santhera Launches U.S. Expanded Access Program with Idebenone for Patients with Duchenne Muscular Dystrophy (DMD)
06/02/2018
Liestal, Switzerland, February 6, 2018 - Santhera Pharmaceuticals (SIX: SANN) announces the launch of a U.S. Expanded Access Program (EAP) referred to as BreatheDMD with idebenone for patients with DMD. Through the [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
06/02/2018
REGULATED INFORMATION GHENT, Belgium, 6 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
06/02/2018
REGULATED INFORMATION GHENT, Belgium, 6 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
Idorsia announces financial results for 2017 - company off to a great start - 4 compounds to enter Phase 3 development
06/02/2018
Allschwil, Switzerland - 06 February 2018 - Idorsia Ltd (SIX: IDIA) today announced its financial results as of December 31, 2017, which represent the business activities for the six and a half months since the demerger [...]
Targovax ASA: Invitation to fourth quarter and full year 2017 results presentation Thursday 15 February
06/02/2018
Oslo, Norway, 6 February 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its fourth quarter 2018 results on Thursday, 15 [...]
BCPhA Response to B.C. Government Retail Framework for Non-Medical Cannabis
06/02/2018
VANCOUVER, British Columbia, Feb. 05, 2018 (GLOBE NEWSWIRE) -- The BC Pharmacy Association (BCPhA) applauds the B.C. Government’s decision to make a clear distinction between non-medical cannabis and medical cannabis by [...]
Burcon NutraScience Announces Transfer of Listing to Nasdaq Capital Market
06/02/2018
VANCOUVER, British Columbia, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Burcon NutraScience Corporation (TSX: BU ) (NASDAQ: BUR ) (“Burcon” or the “Company”), a leader in natural product extraction, purification and isolation [...]
Correction from source: Aurora Spine Announces Upsizing of Private Placement
06/02/2018
CARLSBAD, Calif., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (TSX-V: ASG ) ("Aurora Spine" or the "Company") is pleased to announce that, as a result of strong investor demand, it has increased the size [...]
BeiGene Announces Commercial Availability of VIDAZA® (Azacitidine for Injection) in China
06/02/2018
BEIJING, China, and CAMBRIDGE, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE ), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly [...]
Aurora Spine Announces Upsizing of Private Placement
05/02/2018
CARLSBAD, Calif., Feb. 05, 2018 (GLOBE NEWSWIRE) -- THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE [...]
Ari Kellen Acquires Common Shares of Vaxil Bio Ltd.
05/02/2018
TORONTO, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Ari Kellen announces that on January 26, 2018, he acquired (the " Acquisition ") by way of private placement ownership over 4,985,000 units (" Units ") of Vaxil Bio Ltd. (TSXV: [...]
BeiGene to Present Tislelizumab Data in Urothelial Carcinoma at the 2018 Genitourinary Cancers Symposium
05/02/2018
CAMBRIDGE, Mass. and BEIJING, China, Feb. 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE ), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly [...]
ImmuCell to Announce Financial Results for Fourth Quarter and Full Year 2017
05/02/2018
PORTLAND, Maine, Feb. 05, 2018 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC ) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and [...]
Results from Phase I Study of CB-839 in Combination with Everolimus or Cabozantinib in Patients with Renal Cell Carcinoma to be Presented at the 2018 American Society of Clinical Oncology Genitourinary Cancer Symposium
05/02/2018
-Overall response rate of 40% and 100% disease control rate in advanced clear cell renal cell carcinoma patients treated with CB-839 plus Cabozantinib -Randomized placebo controlled CANTATA Phase 2 trial of CB-839 in [...]
Mesa Labs Reports Third Quarter Results
05/02/2018
LAKEWOOD, Colo., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB ) (we, us, our, “Mesa” or the “Company”) today reported its results for the third quarter ended December 31, 2017. Revenues for [...]
Argos Obtains Option to License PD1 Checkpoint Inhibitors
05/02/2018
- Data showing synergy between PD1 checkpoint inhibition and analogue of Rocapuldencel-T in a preclinical model of renal carcinoma presented at ASCO-SITC - - Company to host a conference call on Tuesday, February 6, [...]

Pages